Patrick Hwu: How can we enhance the immune response against cancer metastases?
Patrick Hwu shared a post on LinkedIn:
“How can we enhance the immune response against cancer metastases?
Using both mouse models and human tissue samples from Colon Cancer liver metastases, Zhang et al. demonstrate that patients with better outcomes had tumors containing tertiary lymphoid structures (TLS) with plasma cells making tumor-specific IgG antibodies and that intratumoral injection of the chemokine CCL19 could increase TLS formation and improve the antitumor immune response.”
Source: Patrick Hwu/LinkedIn
Authors: Yifan Zhang, Guangjian Liu, Qianwen Zeng, Wenrui Wu, Kai Lei, Chuankai Zhang, Miaoling Tang, Yuting Zhang, Xiao Xiang, Li Tan, Rui Cui, Si Qin, Xinming Song, Changjun Yin, Zhihang Chen, and Ming Kuang.
Dr. Patrick Hwu, MD, currently serves as the President and CEO of Moffitt Cancer Center. With a focus on understanding the dynamics between tumors and the immune system, Dr. Hwu’s research has been pivotal in advancing gene-modified T cell therapy. He notably contributed seminal work on the development of the first chimeric antigen receptor aimed at combating cancer. His research portfolio extends to vaccines, adoptive T-cell therapies, and mechanisms of immune resistance.
Before joining, Dr. Hwu held numerous leadership roles at The University of Texas MD Anderson Cancer Center for over 17 years. Notably, he served as the inaugural Chairman of the Department of Melanoma Medical Oncology in 2003, as well as the Associate Director of the Center for Cancer Immunology Research. Additionally, he chaired the Department of Sarcoma Medical Oncology, demonstrating his commitment to advancing cancer treatment and research.